No black box warning on record for Combipatch (estradiol/norethindrone Acetate Transdermal System)

As of the latest FDA labeling reviewed, Combipatch (estradiol/norethindrone Acetate Transdermal System) (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM) does not carry a black box warning. Standard warnings and precautions still apply — see the full Combipatch (estradiol/norethindrone Acetate Transdermal System) medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS See BOXED WARNING . 1. Cardiovascular Disorders An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy. An increased risk of stroke and DVT has been reported with estrogen-alone therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately. Risk factors for arterial vascular dis

No black box warning on record for Combipatch (estradiol/norethindrone Acetate Transdermal System)

Other warnings & precautions

WARNINGS See BOXED WARNING . 1. Cardiovascular Disorders An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy. An increased risk of stroke and DVT has been reported with estrogen-alone therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately. Risk factors for arterial vascular dis

Combipatch (estradiol/norethindrone Acetate Transdermal System) Black Box Warning

No black box warning on record for Combipatch (estradiol/norethindrone Acetate Transdermal System)

Other warnings & precautions

Combipatch (estradiol/norethindrone Acetate Transdermal System) Black Box Warning

No black box warning on record for Combipatch (estradiol/norethindrone Acetate Transdermal System)

Other warnings & precautions